scispace - formally typeset
G

Gary K. Schwartz

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  305
Citations -  24375

Gary K. Schwartz is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 75, co-authored 249 publications receiving 22069 citations. Previous affiliations of Gary K. Schwartz include Cornell University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

Ki Y. Chung, +13 more
- 20 Mar 2005 - 
TL;DR: Colorectal cancer patients with EGFR-negative tumors have the potential to respond to cetuximab-based therapies, and selection or exclusion of patients for cetUXimab therapy on the basis of currently available EGFR IHC does not seem warranted.
Journal ArticleDOI

Targeting the Cell Cycle: A New Approach to Cancer Therapy

Gary K. Schwartz, +1 more
- 20 Dec 2005 - 
TL;DR: There are now agents that abrogate the cell cycle checkpoints at critical time points that make the tumor cell susceptible to apoptosis, and an understanding of thecell cycle is critical to understanding how best to clinically develop these agents.
Journal ArticleDOI

KIT as a therapeutic target in metastatic melanoma

Richard D. Carvajal, +17 more
- 08 Jun 2011 - 
TL;DR: Among patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients, indicating positive selection for the mutated allele.
Journal ArticleDOI

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, +27 more
- 28 Jan 2013 - 
TL;DR: Safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel LNP-formulated RNAi therapeutic in patients with cancer are shown, providing proof-of-concept for RNAi therapeutics in humans and the basis for further development in cancer.